Partnerships with fellow nonprofits in dermatology and psoriasis allow us to share our knowledge, collaborate on important projects, and collectively advocate for improved treatment of patients worldwide.
Atopic Dermatitis and Psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time, and response to treatment. BIOMAP will examine the causes and mechanisms of Atopic Dermatitis and Psoriasis to enable optimal treatments and an individualized therapy scheme for each patient. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm, from re-active to pro-active strategies that encompass disease biology and life-time trajectory, matching the intervention with endotypes.
The International Federation of Psoriasis Associations (IFPA) is a nonprofit organization uniting national and regional psoriasis associations from around the world. Since being founded in 1971, they have worked to resolve the challenges facing the international psoriasis community. IFPA campaigns on behalf of all people with psoriasis and psoriatic arthritis. Their goals are to empower their members, improve living conditions for patients, raise awareness of psoriasis and psoriatic arthritis, and cooperate with fellow stakeholders.
Officially founded in 1935, the International League of Dermatological Societies (ILDS) has been promoting skin health around the world for over 80 years. Its forerunner began in 1889 as the first of many World Congresses of Dermatology. Today, the ILDS represents dermatology at the highest level with over 180 Member Societies from more than 80 countries, representing over 200,000 dermatologists. ILDS works closely with partners around the world including the World Health Organization (WHO), with whom ILDS is in official relations, to improve skin health for all people around the world.
PsoProtect is an international registry for health care providers to report outcomes of COVID-19 in individuals with psoriasis. The information provided informs clinicians when assessing risk and treating COVID-19 in patients with psoriasis and other immune-mediated inflammatory diseases. It will help improve the understanding of how factors such as immunomodulator therapies and comorbidities affect outcomes of COVID-19 in psoriasis. PsoProtect provides regular, open access summaries of all reported cases in PsoProtect, for the benefit of the international psoriasis community.